DK2888239T3 - Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner - Google Patents

Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner Download PDF

Info

Publication number
DK2888239T3
DK2888239T3 DK13759081.6T DK13759081T DK2888239T3 DK 2888239 T3 DK2888239 T3 DK 2888239T3 DK 13759081 T DK13759081 T DK 13759081T DK 2888239 T3 DK2888239 T3 DK 2888239T3
Authority
DK
Denmark
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
ophthalmic pharmaceutical
ophthalmic
Prior art date
Application number
DK13759081.6T
Other languages
English (en)
Inventor
Wha Bin Im
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2888239T3 publication Critical patent/DK2888239T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Claims (11)

1. Forbindelse med formlen (III) eller farmaceutisk acceptabelt salt deraf:
hvor n er 3 til 10; R2D ved hver forekomst uafhængigt af hinanden er hydrogen eller hydroxyl; og 1, 2, 3, 4, 5 eller 6 R2D-substituenter ikke er hydrogen.
2. Forbindelse ifølge krav 1, der har en hvilken som helst af de følgende formler (IV) til (VIIp):
3. Oftalmisk farmaceutisk sammensætning, der omfatter forbindelsen eller det farmaceutisk acceptable salt deraf ifølge et hvilket som helst af kravene 1 eller 2 og en farmaceutisk acceptabel bærer.
4. Forbindelse ifølge et hvilket som helst af kravene 1 og 2 eller oftalmisk farmaceutisk sammensætning ifølge krav 3 til anvendelse i en fremgangsmåde til behandling af en oftalmisk sygdom hos et menneske, hvilken fremgangsmåde omfatter administration af en terapeutisk effektiv mængde af forbindelsen eller sammensætningen til et individ, som har behov derfor.
5. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor administrationen er topisk administration.
6. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor sygdommen er glaukom.
7. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor sygdommen er makuladegeneration.
8. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor sygdommen er en følge af intraokulært tryk.
9. Forbindelse ifølge et hvilket som helst af kravene 1 og 2 eller oftalmisk farmaceutisk sammensætning ifølge krav 3 til anvendelse i en fremgangsmåde til reduktion af hornhindefortykkelse, hvilken fremgangsmåde omfatter
administration afen terapeutisk effektiv mængde af forbindelsen eller sammensætningen til et individ, som har behov derfor.
10. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 9, hvor individet lider af glaukom.
11. Forbindelse eller oftalmisk farmaceutisk sammensætning til anvendelse ifølge krav 9, hvor individet lider af okulær hypertension.
DK13759081.6T 2012-08-27 2013-08-23 Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner DK2888239T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693437P 2012-08-27 2012-08-27
PCT/US2013/056418 WO2014035827A1 (en) 2012-08-27 2013-08-23 Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Publications (1)

Publication Number Publication Date
DK2888239T3 true DK2888239T3 (da) 2019-03-04

Family

ID=49117974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13759081.6T DK2888239T3 (da) 2012-08-27 2013-08-23 Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner

Country Status (12)

Country Link
US (2) US9024042B2 (da)
EP (1) EP2888239B1 (da)
JP (1) JP6270848B2 (da)
KR (2) KR102304111B1 (da)
CN (1) CN104684904B (da)
AU (1) AU2013309124B2 (da)
CA (1) CA2882743C (da)
DK (1) DK2888239T3 (da)
ES (1) ES2711425T3 (da)
HK (1) HK1211031A1 (da)
TR (1) TR201900863T4 (da)
WO (1) WO2014035827A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882743C (en) 2012-08-27 2021-11-30 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
JP6626831B2 (ja) * 2014-02-20 2019-12-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中心肥厚の減少
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
US9573926B2 (en) 2014-05-22 2017-02-21 Allergan, Inc. Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use
WO2016054596A1 (en) 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
PL3752501T3 (pl) 2018-02-13 2023-08-21 Gilead Sciences, Inc. Inhibitory pd-1/pd-l1
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU5436198A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE10322843A1 (de) 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
US20060135609A1 (en) * 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US20070254920A1 (en) 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
JP5570807B2 (ja) * 2006-07-11 2014-08-13 アラーガン インコーポレイテッド 抗緑内障薬としてのシクロペンタン誘導体
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7732443B2 (en) 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
US7737140B2 (en) * 2008-04-24 2010-06-15 Allergan, Inc. Therapeutic compounds
CA2724271A1 (en) * 2008-05-15 2009-11-19 Allergan, Inc. Therapeutic substituted cyclopentanes
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
CA2882743C (en) 2012-08-27 2021-11-30 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Also Published As

Publication number Publication date
EP2888239B1 (en) 2018-11-28
KR20200110820A (ko) 2020-09-25
US9427401B2 (en) 2016-08-30
US20140057975A1 (en) 2014-02-27
KR102304111B1 (ko) 2021-09-23
CN104684904A (zh) 2015-06-03
CN104684904B (zh) 2017-10-13
CA2882743A1 (en) 2014-03-06
TR201900863T4 (tr) 2019-02-21
AU2013309124A1 (en) 2015-03-12
KR20150046269A (ko) 2015-04-29
HK1211031A1 (en) 2016-05-13
AU2013309124B2 (en) 2018-03-01
US20150322036A1 (en) 2015-11-12
US9024042B2 (en) 2015-05-05
WO2014035827A1 (en) 2014-03-06
CA2882743C (en) 2021-11-30
JP6270848B2 (ja) 2018-01-31
JP2015528463A (ja) 2015-09-28
ES2711425T3 (es) 2019-05-03
EP2888239A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
DK2888239T3 (da) Reduceret central hornhindefortykkelse ved anvendelse af hydrofile esterprodrugs af beta-chlorcyclopentaner
DK3107906T3 (da) Reduceret central hornhindefortykkelse under anvendelse af hydrofile ester-prodrugs af beta-chlorcyclopentaner
US9090595B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
EP3201192B1 (en) Ester prodrugs of gamma-lactams and their use
US8609658B2 (en) N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
US9315486B2 (en) Therapeutic cyclopentanols, compositions thereof, and methods for use thereof